A meta-analysis has demonstrated consistent efficacy in heart failure outcomes with SGLT2 inhibitors regardless of disease ...
There is a strong opportunity in the heart failure (HF) space for new agents that could reduce HF-associated hospitalisations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results